Dementia

Comprehensive excellence in dementia – driven by patients, powered by science

The PPD™ clinical research business of Thermo Fisher Scientific is a **global leader** in dementia drug development, with unmatched multifaceted experience across **Alzheimer's Disease, Frontotemporal Lobe Dementia (FTD), and Lewy Body Dementia**. Our success spans all phases of development, proven track record of **exceeding enrollment** goals in Alzheimer's disease.

Our integration with Thermo Fisher Scientific's CDMO solutions enable seamless transitions **from discovery to manufacturing and clinical execution**. **We leverage next-generation proteomics to expedite biomarker discovery and a combination of digital-health and patient-centered approaches to enhance trial access and experience – while enabling regulatory-grade real-world insights**.

In the past five years

- **29** dementia studies
- **1,400+** sites
- **6,200+** patients



Expertly engineered trials for every type of dementia. We have the experience and expertise to successfully conduct Alzheimer's disease studies and navigate complex regulatory processes.

Our Alzheimer's studies involved:

- Symptomatic treatment and disease modification approaches
- Pre-symptomatic patient identification and intervention
- Phase I and dose ranging
- Implementation of NIA-AA 2024 criteria through fluid-based biomarkers and imaging

Our therapeutically aligned project teams are well versed in considerations often unique to Alzheimer's research, which helps ensure the safety of a vulnerable subject population.

Thermo Fisher SCIENTIFIC

Dementia clinical trial experience

Indication	Number of studies in the past 5 years	Key Differentiators
Alzheimer's Disease (AD) Disease Modifying	10	• Advanced imaging and fluid biomarker logistics • Access to PET, CSF, plasma biomarker testing • Screen failure mitigation via pre-screening tools • Extensive Expertise in cognitive and functional scales • Targeted eligibility review
Alzheimer's Disease Symptom Reducing	6	• Skilled raters for neuropsychiatric symptoms • Recruitment of moderate-to late-stage patients, with caregivers • Placebo-run in and relapse prevention • Deep engagement and burden mitigation strategies • Scientific Surveillance
Alzheimer's Disease Gene Therapy	2	• Genetic pre-screening infrastructure including counselling • Experience with CNS-targeted GT (C1-C2 administration, vectors immunogenicity) • Safety monitoring and long-term follow-up • Early phase adaptive design trials
Alzheimer's Disease Diagnostic	1	• Centralized imaging (PET/MRI) • Partnership with imaging cores and global tracer logistics
Alzheimer's Disease Prevention	1	• Recruitment from genetic registries • Regularory familiarity with primary and secondary prevention trial design
Frontotemporal Lobe Dementia	8	• Genetic screening infrastructure (GRN, C9orf72) • Access to presymptomatic populations • Capability to manage neuropsychiatric symptomology • Hyper-targeted recruitment and "white-glove" site management • Use of advanced imaging and fluid biomarkers
Dementia with Lewy Bodies	1	• Use of DLB-specific criteria for diagnosis • Ability to manage high comorbidities • Familiarity with complex endpoint batteries

With unmatched expertise in dementia, our **300+ managers** and seasoned leadership team (180+ years of experience) deliver tailored, patient-centered trial designs. We guarantee regulatory compliance, enhance patient experience, and deliver swift, exceptional outcomes.

Learn more at **thermofisher.com/ppd**

ppd